Acyclovir is known for its antiviral activity against some pathogenic viruses such as the Epstein-Barr virus (EBV) that causes infectious mononucleosis (IM) and IM-like illness. Therefore, we empirically administered acyclovir to patients with suspected EBV-IM and IM like-illness, upon their admission to our hospital. We admitted 25 patients, who were hospitalized for fever and lymphadenopathy, to the Tohoku University Hospital Infectious Disease Ward. As part of treatment, 8 of these patients were given acyclovir (750 mg/day) with their consent and were assigned to the acyclovir group; the remaining 17 patients were assigned to the control group. The mean age of acyclovir patients (all men) was 42 ± 5.2 years, and that of control patients (13 men and 4 women) was 31 ± 3.0 years. The cause of illness was confirmed as EBV-IM in 6 patients (1, acyclovir; 5, control), and remained unknown for the other 19 IM-like illness patients (7, acyclovir; 12, control). A shorter duration of hospitalization and fever was observed in the acyclovir compared to that in the control patients (hospitalization duration: 16 ± 3.7 vs. 27 ± 7.7 days, P = 0.36; fever duration: 4.5 ± 1.8 vs. 18 ± 6.5 days, P = 0.04). Additionally, serum amyloid A (SAA) levels were lower in acyclovir than that in control patients (98 ± 37 vs. 505 ± 204 μg/mL, P = 0.02). Therefore, we propose that acyclovir is a potential therapeutic agent for both EBV-IM and IM like-illnesses. Future studies should further examine its mechanism of action.
Infectious mononucleosis (IM) is specifically caused by the Epstein-Barr virus (EBV), and is characterized by lymphadenopathy, prolonged fever, cervical lymph node swelling, and increased inflammatory reaction (Luzuriaga and Sullivan 2010) . IM-like illness, which also has non-EBV etiologies, exhibits similar characteristic symptoms as IM. In the US, adult IM and IM-like illness are caused by EBV in 50-90% of the cases, human herpes virus type 6 (HHV6) in 9%, cytomegalovirus (CMV/HHV5) in 5-7%, herpes simplex virus (HSV)-1 in 6%, human immunodeficiency virus (HIV) in < 2%, and adenovirus in < 1% of the cases (Hurt and Tammaro 2007) . However, IM-like illness due to CMV infection appears to be more common in Japan than in the US, and has been reportedly associated with 27.5% of IM-like illness cases in Japan (Naito et al. 2006 ). An evaluation and treatment algorithm involving patient history, physical examination, symptoms, and size of neck mass has been proposed (Schwetschenau and Kelley 2002) .
The outcome of antiviral therapy largely depends on the pathogen. However, it would be impractical to test for all possible viruses due to time and cost constraints. Consequently, EBV-IM cases have been the ones most extensively studied with the aim of improving diagnosis and management, which resulted in the identification of RT-PCR as a useful tool for early diagnosis (Vouloumanou et al. 2012) . Unfortunately, no anti-viral drug has been approved yet for the treatment of EBV-IM, and clinical trials involving anti-viral drugs have also yielded controversial results. On the other hand, administration of acyclovir to EBV patients reportedly gave beneficial results in immunocompetent patients (Torre and Tambini 1999; Rafailidis et al. 2010) . One study showed that acyclovir pharmacokinetic parameters did not correlate with the virologic or clinical response in young adults with EBV-IM (Vezina et al. 2010) . However, another study reported that valacyclovir therapy led to reduced EBV excretion and was clinically beneficial (Balfour et al. 2007 ). Other studies also showed that high-dose acyclovir and valacyclovir prophylaxis reduced the risk of CMV infection and disease following bone marrow transplantation, although it did not improve overall survival (Prentice et al. 1994 ); a more recent report revealed that antiviral agents such as ganciclovir or foscarnet should be used to treat CMV disease (Boeckh 2011) . Neonatal HSV infection, caused by exposure to HSV in the genital tract during delivery, often results in severe fever and has a survival rate of 50% only. Antiviral therapy with high-dose acyclovir reportedly led to a reduction in the mortality of infants with disseminated disease (Corey and Wald 2009 ). The number of genital HSV infections among adults has increased in the last 30 years (Corey 2002) . Varicella zoster virus (VZV), which belongs to the subfamily Alphaherpesvirinae, is commonly treated by nucleosides such as acyclovir, famciclovir, and valacyclovir (Rajan and Rivers 2001) . These antiviral drugs have been approved for the treatment of herpes zoster and have shown beneficial results in reducing the duration of established postherpetic neuralgia. Although acyclovir anti-viral activity against herpes virus HHV8 could not be detected in vitro, some anti-herpes virus 6 activity was observed (De Clercq et al. 2001) . One case report also showed that ganciclovir was effective in the treatment of adenovirus-associated hemorrhagic cystitis (Chen et al. 1997 ).
As described above, acyclovir seems to be potentially beneficial in the treatment of IM and IM-like illness. Therefore, we conducted this retrospective study involving IM and IM-like illness patients whose treatment empirically included or excluded acyclovir. We especially investigated the cases where patients were given acyclovir for the treatment of suspected viral infection upon admission to our hospital, and we examined the effects of this drug on patient condition.
Methods

Patients
In this retrospective cohort study, we collected data involving patients who were hospitalized for fever (> 37.5°C) and lymphadenopathy, from 2008 to 2010, at the Tohoku University Hospital Infectious Disease Ward. Since "conventional" IM diagnostic criteria only apply to EBV-caused IM, we enrolled 25 patients in this study, including patients with IM-like illness caused by other viruses, with the following inclusion criteria: duration of fever was defined as > 37.5°C for at least 1 day; sputum examination, including tuberculosis smear and PCR, did not indicate any bacterial infection; blood bacterial cultures were also negative for aerobes, anaerobes, and fungi; no antibodies against toxoplasma, chlamydia pneumonia, and mycoplasma were detected; antinuclear antibodies, indicating collagen diseases, did not exceed normal levels; sarcoidosis was excluded; HIV antibody and HIV RT-RNA levels were below the detection limit; lymphoma was not detected in any of the patients who underwent bone-marrow puncture and 18F-2-deoxy-fluoro-d-glucose positron emission tomography.
SRL laboratories (Tokyo, Japan) were used to perform HHV 1-8 viral PCR, assess HIV RNA quantity, conduct the CMV antigenemia (pp65 antigenemia, a component of the shell surrounding the virus nucleoprotein core) assay, and measure anti-EBV VCA IgG, IgM, and IgA as well as anti-EBV EA IgG and IgA and Epstein-Barr virus nuclear antigen (EBNA) antibody levels. EBV antibodies were measured using the fluorescent antibody technique, and antibodies against other viruses were measured using enzyme immunoassay (EIA). HIV antibody titrations were assessed at a Tohoku University clinical laboratory using the EIA method.
Statistical analysis
We expressed analyzed data as mean ± standard deviation. Comparisons between pre-treatment and post-treatment of the acyclovir and control groups were calculated by subtracting the post-treatment value from the pre-treatment value. The Mann-Whitney's U test was used to calculate the P values of the 2 groups. The KruskalWallis test was used to evaluate clinical improvement. A P value < 0.05 was considered statistically significant. Analysis of data was performed using EXCEL software.
Results
Eight of the 25 patients were given acyclovir with their consent, as part of conventional therapy. Patient characteristics are presented in Table 1 . Mean age, physical examination results, and laboratory results were compared between control patients (CP) and acyclovir patients (AP). Whereas all 8 APs were men, 13 of the CPs were men and 4 were women (P = 0.13). In general, clinical presentations including palpable surface lymph nodes (lymphadenopathy), severe throat pain (pharyngeal pain), continuous headache (headache), major multiple polyarthralgia (arthralgia), rash covering more than 1% of the body surface area (rash), and multiple mucosal bleeding (mucosal bleeding) were not significantly different between CPs and APs (P > 0.05). The largest liver and spleen diameter measurements observed also were not significantly different between CPs and APs (P = 0.90 and P = 0.37, respectively). Only the neck flexion test results were significantly different between the 2 groups (P = 0.01), and the 3 APs with positive neck flexion test results were clinically suspected of viral meningitis based on collected spinal fluid. Based on blood samples collected upon admission, laboratory test results showed that hemoglobin concentration, white blood cell count (WBC), white blood cell differentiation, platelet cell count, as well as C-reactive protein (CRP), serum amyloid A (SAA) proteins, ferritin, soluble IL-2 receptor (sIL-2R), lactate dehydrogenase (LDH), d-dimer, glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) levels were not significantly different between the 2 groups (P > 0.05).
Antibody titer tests were performed, and viral DNA was detected using PCR in order to identify the causes of fever; results are shown in Table 2 . Patients with acute EBV infection were defined as those with anti-EBV VCA IgM positive (> 10) and EBNA negative (< 10) results. Accordingly, 5 CPs and 1 AP met the clinical criteria identifying acute EBV infection as the cause of IM. Since CMV antigenemia test results were negative for all patients, IM-like illness was unlikely caused by CMV. PCR results were positive for EBV DNA (> 10 copies/500,000 cells) in peripheral blood mononuclear cell (PBMC) samples of 2 CPs and 3 APs. Since PCR results were negative for HSV, CMV, VZV, or HHV DNA (< 10 copies/500,000 cells) in all patients, the pathogen was only identified in the EBV patients.
Acyclovir (750 mg/day) was daily administered intravenously with normal saline, as part of the treatment. The duration of treatment was similar between CPs and APs. Adverse effects of acyclovir such as skin eruption, liver injury, and shock were not observed in any patients. Antibiotic therapy was administered to 4 CPs and 4 APs, and gamma globulin was administered to 2 APs. The anti- biotic and gamma globulin treatments did not affect the patients' laboratory results. Blood was collected from CPs and APs over a period of 2-3 days following acyclovir treatment. When we subtracted the laboratory examination post-treatment values from the pre-treatment values, the decline in WBC count was less prominent in the CP group (888 ± 848 × 10 tion in CRP and ferritin levels was similar in APs and CPs (CRP, P = 0.40; ferritin, P = 0.75), SAA levels were significantly lower in APs (505 ± 204 μg/mL) than in CPs (98 ± 37 μg/mL; P = 0.02). Acyclovir administration also caused an increase in sIL-2R levels in APs (−51 ± 84 U/mL) and a reduction in CPs (341 ± 123 U/mL), although the change was not statistically significant (P = 0.55).
The duration of hospitalization was more prominently reduced in APs (16 ± 3.7 days) than in CPs (27 ± 7.7 days; P = 0.36), as was the duration of fever in APs (4.5 ± 1.8 days) compared to that in CPs (18 ± 6.5 days; P = 0.04), as shown in Table 4 . The mean hospitalization period among EBV-IM patients was 18 days for the 1 AP and 12 ± 15.3 Table 3 . Comparison between pre-treatment and post-treatment laboratory examination results. Table 4 . Duration of hospitalization and of fever.
Hospitalizaion (days) 27 ± 7.7 16 ± 3.7 0.36
Fever (days) 18 ± 6.5 4.5 ± 1.8 0.04 Table 5 . Bilateral lymphadenopathy symptoms worsened in 13 of the 17 CPs, but dramatically improved in 6 APs (P = 0.01). Pharyngeal pain was alleviated in 8 CPs and 6 APs (P = 0.16), and headache had subsided in significantly more APs than CPs (P < 0.01). Moreover, improvement in arthralgia symptoms was observed in 5 CPs and 6 APs (P < 0.01), and mucosal bleeding improved more significantly among APs than CPs (P < 0.01). On the other hand, rash was similarly observed in CPs and APs (P = 0.17). In general, acyclovir reduced tissue inflammation and symptoms associated with it such as lymphadenopathy, headache, arthralgia, and mucosal bleeding.
Discussion
In this study, we demonstrated the benefits of empirical acyclovir treatment of IM and IM-like illness patients. Acyclovir reduced the duration of hospitalization and of fever; it also led to a rapid decline in the levels of the acute inflammatory marker SAA, within a period of time shorter than the half-life time of ferritin and CRP, which is a chronic inflammation marker. Additionally, acyclovirmediated improvement in vital signs such as fever, which is indicative of increased inflammatory cytokine secretion as part of the immunological response against the pathogen, was correlated with the laboratory findings. The recovery of neutrophil count was also more prominent than that of lymphocyte count in APs.
The mechanism behind the beneficial effects of acyclovir on AP condition is unknown. One possible explanation is that acyclovir anti-viral activity also inhibits the DNA replication of viruses other than HHV1 to 3. According to a previous study, acyclovir did not exhibit activity against HHV-7 infection (Zhang et al. 1999) . On the other hand, acyclovir combined with interferon-beta demonstrated anti-CMV activity in vitro (Spector et al. 1982) . Acyclovir antiviral activity against EBV was also reported in vitro (Long et al. 2003) . Some studies have shown that acyclovir combined with prednisolone inhibits replication of oropharyngeal EBV without affecting the duration of IM clinical symptoms (Ernberg and Andersson 1986; Tynell et al. 1996) . However, no studies have yet reported clinical data indicating that acyclovir is effective in the treatment of EBV-IM and IM-like illness in vivo.
Another possible explanation is that acyclovir exhibits anti-inflammatory activity through suppressing virusinduced cytokine secretion. Studies have reported that HSV enhances the expression of cytokines such as interferon-gamma and tumor necrosis factor-alpha, and that EBV can immortalize B cells activated by cytokines (Wendel-Hansen et al. 1994; Chen et al. 2000) . Interestingly, a previous study has reported that acyclovir blocks the expression of inflammatory cytokines (Halford et al. 1997) . Moreover, recent reports have shown that antibiotics such as minocycline or macrolides demonstrate antiinflammatory activity in addition to their known function (Amin et al. 1996) .
However, the present study had several disadvantages. For instance, it included a small number of patients, and only clinical features and conventional markers were examined. Therefore, future studies should include a larger number of cases and additional clinical markers such as galectin-9 or osteopontin, which reflect disease activity, should be examined (Chagan-Yasutan et al. 2009; Saitoh et al. 2012 ).
In conclusion, treatment with acyclovir reduced the duration of hospitalization and of fever without having any evident adverse effects. Therefore, acyclovir treatment may be effective in treating patients suspected of having a viral infection. Additionally, after experiencing a severe earthquake followed by a tsunami in March of 2011 (Shibahara 2011) , we observed that, in such resource-limited conditions, acyclovir treatment could constitute one of the initial empirical therapies for IM-like patients.
